A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

Inclusion Criteria: * Keloid scar located below the neck between 1 and 3 cm long and less than 1 cm at its widest point * Willing to undergo keloid scar excision surgery * Healthy adult male or non-pregnant female * Non-diabetic * Body Mass Index in the range of 18-35 * No clinically significant abnormal values on a full blood safety screen * Non-smoker and non-nicotine user for the previous six months Exclusion Criteria: * History or clinical evidence of acute or chronic disease * History of cancer within the last 5 years, except for surgically removed cancers of the skin that are not near the keloid area * History of anaphylactic shock or anaphylactoid (hypersensitivity) reaction * Allergy to local anesthesia, including lidocaine and epinephrine * Dermatologic disorders, except for folliculitis and acne * On therapy with steroids * On therapy with a drug that would affect collagen synthesis * Positive urine test for nicotine or drugs of abuse * Positive blood test for HIV 1 or 2, hepatitis B or hepatitis C * Positive blood test for anti-AZX100 antibodies * Participation in another study within 60 days prior to enrollment * Blood donation within 7 days before dosing with study drug * Plasma donation within 3 days before dosing with study drug * Tattoo within approximately 3 cm of the keloid scar that will be removed * Apply any lotion or cream on or near the keloid scar that will be removed within 14 days before dosing with study drug * Use of a tanning bed or tanning light within the 3 months before enrollment * Intend to use any scar improving product during of the study (1 year) * History of drug addiction or excessive use of alcohol * Previous drug treatment of the keloid scar within the last 3 years, or have had any laser, irradiation, or surgical treatment of the keloid scar that will be removed